Intended for healthcare professionals


Clarification of comments on trial of aminosidine in visceral leishmaniasis

BMJ 1998; 317 doi: (Published 31 October 1998) Cite this as: BMJ 1998;317:1250
  1. P Olliaro, Manager, steering committee on drugs for malaria (CHEMAL),
  2. T K Jha, Medical director
  1. UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases, Geneva, Switzerland
  2. Kala-Azar Research Centre Muzaffarpur, Bihar, India

    EDITOR—We would like to clarify five points in relation to Lockwood's commentary on our randomised controlled trial of aminosidine (paromomycin) for treating visceral leishmaniasis in Bihar, India.1

    Patients being screened for possible inclusion in the study were tested for HIV infection; all of the 120 patients included were negative for HIV. None of the patients tested (around …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription